TD Cowen Upgrades Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) to “Strong-Buy”

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) was upgraded by equities research analysts at TD Cowen to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Several other brokerages have also recently weighed in on DMRA. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Wedbush boosted their price objective on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, July 30th. Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They set a “buy” rating and a $50.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $44.00.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of DMRA stock opened at $30.31 on Monday. The company has a market capitalization of $1.87 billion, a P/E ratio of -8.99 and a beta of 1.47. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $2.45 and a fifty-two week high of $38.33. The stock has a 50 day moving average price of $28.50 and a two-hundred day moving average price of $26.62.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.06. As a group, equities analysts predict that Damora Therapeutics, Inc. Common Stock will post -1.98 earnings per share for the current year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Several large investors have recently added to or reduced their stakes in DMRA. Janus Henderson Group PLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $40,000. Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $266,000. Virtu Financial LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at about $49,000. Sigma Planning Corp bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $334,000. Finally, Two Sigma Investments LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock during the third quarter valued at about $76,000. Institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.